Mapracorat

Drug Profile

Mapracorat

Alternative Names: BAY-865319; BOL-303242-X; ZK-245186

Latest Information Update: 28 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bausch & Lomb; Bayer HealthCare Pharmaceuticals
  • Class Anti-inflammatories; Corticosteroids; Skin disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Psoriasis
  • Discontinued Allergic conjunctivitis; Atopic dermatitis; Dry eyes; Ocular inflammation; Ocular pain

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Psoriasis in Germany (Topical, Ointment)
  • 31 Aug 2013 Bausch & Lomb completes a phase III trial in Ocular pain & inflammation in USA (NCT01591161)
  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top